Literature DB >> 29045937

Adenovirus-Mediated Expression of BMP-2 and BFGF in Bone Marrow Mesenchymal Stem Cells Combined with Demineralized Bone Matrix For Repair of Femoral Head Osteonecrosis in Beagle Dogs.

Wu-Xun Peng1, Lei Wang2.   

Abstract

BACKGROUND: This study investigated the effect of using adenovirus-mediated expression of bone morphogenetic protein 2 (Ad-BMP-2) and basic fibroblast growth factor (bFGF) in bone marrow mesenchymal stem cells (BMSCs) in combination with a demineralized bone matrix (DBM) to repair osteonecrosis of the femoral head (ONFH) in Beagle dogs.
METHODS: A total of 30 Beagle dogs were selected for the isolation of BMSCs, which were cultured and transfected with the recombinant adenovirus vector Ad-BMP2-bFGF-GFP (carrying BMP-2 and bFGF) or a control adenovirus plasmid (encoding green fluorescent protein (Ad-GFP)). The expression of the transfected BMP-2 and bFGF proteins was detected by Western blotting. After transfection, the BMSCs were induced to undergo osteoblastic differentiation. The DBM was prepared to construct a DBM/BMSC complex. Beagle models of canine femoral head defects and necrosis were established and divided into control, DBM, DBM/BMSC, vector Ad-BMP2-bFGF-GFP and Ad-GFP groups. The composite graft was then implanted, and new bone morphology was visualized via X-ray at 3, 6 and 12 weeks after the operation. Hematoxylin and eosin (HE) staining and Masson's trichrome staining were used to identify new bone formation. Immunohistochemistry was performed to calculate the density of new blood vessels. The compressive and bending strength of the BMSCs was evaluated at 12 weeks after the operation.
RESULTS: BMSCs were successfully isolated. The protein expression of BMP-2 and bFGF was significantly higher in the Ad-BMP-2/bFGF group than the normal and Ad-GFP groups. Compared with the control group, at 12 weeks after the operation, the DBM, DBM/BMSC, vector Ad-BMP2-bFGF-GFP and Ad-GFP groups showed a larger area of new bone, higher X-ray scores, greater neovascularization density, and increased compressive and bending strength. The most significant modifications occurred in thevector Ad-BMP2-bFGF-GFP group.
CONCLUSION: The results indicate that the use of Ad-BMP-2/bFGF-modified BMSCs in conjunction with DBM could successfully repair ONFH in a dog model by promoting bone formation and angiogenesis.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Basic fibroblast growth factor; Bone marrow mesenchymal stem cells; Bone morphogenetic protein 2; Demineralized bone matrix; Osteonecrosis of the femoral head

Mesh:

Substances:

Year:  2017        PMID: 29045937     DOI: 10.1159/000484026

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  14 in total

1.  Cell therapy for osteonecrosis of femoral head and joint preservation.

Authors:  You Seung Chun; Dong Hwan Lee; Tae Gu Won; Chan Sik Kim; Asode Ananthram Shetty; Seok Jung Kim
Journal:  J Clin Orthop Trauma       Date:  2021-11-27

2.  Hip osteonecroses treated with calcium sulfate-calcium phosphate bone graft substitute have different results according to the cause of osteonecrosis: alcohol abuse or corticosteroid-induced.

Authors:  Andrzej Sionek; Adam Czwojdziński; Jacek Kowalczewski; Tomasz Okoń; Dariusz Marczak; Marcin Sibiński; Marcin Złotorowicz; Jarosław Czubak
Journal:  Int Orthop       Date:  2018-03-17       Impact factor: 3.075

3.  Bone morphogenetic protein-2 exhibits therapeutic benefits for osteonecrosis of the femoral head through induction of cartilage and bone cells.

Authors:  Chunhui Wang; Huimei Zang; Dongsheng Zhou
Journal:  Exp Ther Med       Date:  2018-03-09       Impact factor: 2.447

4.  Controlled release of basic fibroblast growth factor from a peptide biomaterial for bone regeneration.

Authors:  WeiKang Zhao; Yuling Li; Ao Zhou; Xiaojun Chen; Kai Li; Sinan Chen; Bo Qiao; Dianming Jiang
Journal:  R Soc Open Sci       Date:  2020-04-01       Impact factor: 2.963

5.  Engineered three-dimensional scaffolds for enhanced bone regeneration in osteonecrosis.

Authors:  Tongtong Zhu; Yutao Cui; Mingran Zhang; Duoyi Zhao; Guangyao Liu; Jianxun Ding
Journal:  Bioact Mater       Date:  2020-04-17

Review 6.  Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease.

Authors:  J Douglas Coffin; Collin Homer-Bouthiette; Marja Marie Hurley
Journal:  J Endocr Soc       Date:  2018-05-28

Review 7.  Multiscale Stem Cell Technologies for Osteonecrosis of the Femoral Head.

Authors:  Yi Wang; Xibo Ma; Wei Chai; Jie Tian
Journal:  Stem Cells Int       Date:  2019-01-08       Impact factor: 5.443

Review 8.  Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes.

Authors:  Jehan J El-Jawhari; Payal Ganguly; Elena Jones; Peter V Giannoudis
Journal:  Bioengineering (Basel)       Date:  2021-05-17

Review 9.  Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research.

Authors:  Rui Li; Qiu-Xia Lin; Xue-Zhen Liang; Guang-Bo Liu; He Tang; Yu Wang; Shi-Bi Lu; Jiang Peng
Journal:  Stem Cell Res Ther       Date:  2018-10-25       Impact factor: 6.832

10.  P53 and Parkin co-regulate mitophagy in bone marrow mesenchymal stem cells to promote the repair of early steroid-induced osteonecrosis of the femoral head.

Authors:  Fei Zhang; Wuxun Peng; Jian Zhang; Wentao Dong; Jianhua Wu; Tao Wang; Zhihong Xie
Journal:  Cell Death Dis       Date:  2020-01-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.